<DOC>
	<DOC>NCT01113333</DOC>
	<brief_summary>Primary Objective: - Assess the safety and tolerability of single intra-articular doses of SAR113945 in patients with knee osteoarthritis. Secondary Objective: - Assess systemic exposure of SAR113945 following intra-articular delivery.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis</brief_title>
	<detailed_description>The total study duration per subject ranges from 4 to 20 weeks broken down as follows: - screening within 4 weeks before dosing, - follow-up of 4 weeks (28 days) after the single dose of study medication, - prolonged by a maximum of 12 weeks if plasma PK level &gt; Limit Of Quantification (LOQ) at Day 28.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Inclusion criteria: Male patients or female patients of non childbearing potential, aged at least 40 years with primary knee osteoarthritis having: Xray or Magnetic Resonance Imaging (MRI) evidence for Kellgren Lawrence Grades II./III joint space narrowing and osteophyte formation, Western Ontario MacMaster (WOMAC) score â‰¦ 72, American College of Rheumatology (ACR) Clinical and Radiographic criteria for osteoarthritis. Exclusion criteria: Any uncontrolled, chronic condition or laboratory finding which, in the opinion of the Principal Investigator, could potentially put the patient at increased risk. Secondary osteoarthritis. Moderate/severe renal impairment. Underlying hepatobiliary disease and/or elevated Alanine Aminotransferase (ALT) &gt; 3 Upper Limit of Normal range. Intraarticular injection within 3 months. Presence of local skin abnormality at the affected knee joint. Unable to be maintained for at least 2 weeks prior to entry into study on paracetamol or metamizole as analgesic. Any Investigational Product within 3 months. Any patient unlikely to comply with the requirements of the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>